China's medical products administrator approved Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Pharma (Xuzhou)'s drug registration for venlafaxine hydrochloride sustained-release tablets.
The drug is indicated for depression, including depression with anxiety, and general anxiety disorder, according to a Thursday filing with the Hong Kong Exchange.
Shares rose 1% in Hong Kong during Friday's trading.
Price (HKD): $13.98, Change: $+0.16, Percent Change: +1.16%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments